BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29105752)

  • 1. Buprenorphine in Neonatal Abstinence Syndrome.
    Kraft WK
    Clin Pharmacol Ther; 2018 Jan; 103(1):112-119. PubMed ID: 29105752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
    Kraft WK; Dysart K; Greenspan JS; Gibson E; Kaltenbach K; Ehrlich ME
    Addiction; 2011 Mar; 106(3):574-80. PubMed ID: 20925688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.
    Gaalema DE; Heil SH; Badger GJ; Metayer JS; Johnston AM
    Drug Alcohol Depend; 2013 Nov; 133(1):266-9. PubMed ID: 23845658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.
    Kraft WK; Gibson E; Dysart K; Damle VS; Larusso JL; Greenspan JS; Moody DE; Kaltenbach K; Ehrlich ME
    Pediatrics; 2008 Sep; 122(3):e601-7. PubMed ID: 18694901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
    Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
    Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.
    Jones HE; Kaltenbach K; Johnson E; Seashore C; Freeman E; Malloy E
    J Addict Med; 2016; 10(4):224-8. PubMed ID: 27244045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for the Treatment of Neonatal Abstinence Syndrome.
    Cook CE; Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):357-365. PubMed ID: 31251931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
    McPherson C
    Neonatal Netw; 2016; 35(5):314-20. PubMed ID: 27636696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breastfeeding promotion for management of neonatal abstinence syndrome.
    Pritham UA
    J Obstet Gynecol Neonatal Nurs; 2013; 42(5):517-26. PubMed ID: 24020477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine: a newer drug for treating neonatal abstinence syndrome.
    Bell SG
    Neonatal Netw; 2012; 31(3):178-83. PubMed ID: 22564314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.
    Kraft WK; Adeniyi-Jones SC; Chervoneva I; Greenspan JS; Abatemarco D; Kaltenbach K; Ehrlich ME
    N Engl J Med; 2017 Jun; 376(24):2341-2348. PubMed ID: 28468518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
    Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
    Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
    Jones HE; Heil SH; Baewert A; Arria AM; Kaltenbach K; Martin PR; Coyle MG; Selby P; Stine SM; Fischer G
    Addiction; 2012 Nov; 107 Suppl 1(0 1):5-27. PubMed ID: 23106923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
    Moore JN; Gastonguay MR; Ng CM; Adeniyi-Jones SC; Moody DE; Fang WB; Ehrlich ME; Kraft WK
    Clin Pharmacol Ther; 2018 Jun; 103(6):1029-1037. PubMed ID: 29516490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
    van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
    Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
    Pritham UA; Paul JA; Hayes MJ
    J Obstet Gynecol Neonatal Nurs; 2012 Mar; 41(2):180-190. PubMed ID: 22375882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
    McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
    J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
    Debelak K; Morrone WR; O'Grady KE; Jones HE
    Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine compared with methadone in opioid-dependent pregnant women: How does it affect neonatal abstinence syndrome?
    Bivin B; Waring A; Alves P
    J Am Assoc Nurse Pract; 2019 Dec; 33(2):119-125. PubMed ID: 31809398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.